QYNAPSE to Present at Sachs 4th Annual Neuroscience Innovation Forum

QYNAPSE is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum (#Sachs_NIF) on April 28-30, 2021. Olivier Courrèges, CEO of QYNAPSE, is pleased to present QYNAPSE’s corporate vision on Day 1 of the Sachs 4th Annual Neuroscience Innovation Forum – which will be held virtually on Wednesday, April 28, 2021 at 2:20 p.m. ET.

Qynapse joins Decentralized Trials & Research Alliance (DTRA) to democratize and accelerate clinical trials

QYNAPSE joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. DTRA plans to unite industry stakeholders to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

QYNAPSE to sponsor and exhibit at the 106th RSNA Annual Meeting and present its latest AI-neuroimaging advancements, which are transforming care for patients with brain disorders

QYNAPSE is pleased to sponsor the 106th Radiology Society of North America (RSNA) Annual Meeting. This year, QYNAPSE is presenting its latest technological advancements of its QyScore® medical device and will also showcase significant developments being made with its QyPredict® AI prediction technology, which is transforming central nervous system (CNS) clinical trials.

QYNAPSE appoints Matt Ullum as Chief Commercial Officer to drive and accelerate its growth globally

QYNAPSE appoints Matt Ullum, CPA, MBA as Chief Commercial Officer. In his new role, Matt assumes overall responsibility for both sales and marketing to accelerate the commercialization of QYNAPSE’s solutions globally. Matt is bringing over 15 years of experience spanning the global pharmaceutical and healthcare industries with a focus on central nervous system (CNS) disorders.

QyPredict®: an AI prediction technology for optimizing patient selection in clinical trials to be presented at the CTAD Conference by QYNAPSE

QYNAPSE will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference. The software computes a cognitive decline risk score that can be used to enrich patient selection strategy with the aim to increase clinical trial success probability.

QYNAPSE (France) and TRUE POSITIVE MEDICAL DEVICES (Canada) are partnering to provide the most advanced AI platform for brain diseases

QYNAPSE today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval – to form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer's, Parkinson's and multiple sclerosis.